FIG 2.

One-way sensitivity analysis to assess impact of individual parameters on cost-effectiveness of treatment arms. In each panel, the dotted line represents the baseline model parameters. (A) One-way analysis of EET versus T2DT. ICERs below zero (solid line) represent parameter values for which EET dominated T2DT. EET dominated T2DT when the cost of echinocandins was <$62, the cost of T2Candida test reagents was >$332, the prevalence of Candida BSI was >7.2%, the number of days to get an alternate diagnosis (uninfected patients) was <4 days, or the reduction in the LOS due to early treatment was >13 days. (B) One-way analysis of FET versus T2DT. ICERs above zero represent parameter values for which FET no longer dominated T2DT. FET no longer dominated T2DT when C. glabrata fluconazole resistance was >20%. (C) One-way analysis of T2DT versus BCDT. ICERs above zero represent parameter values for which T2DT no longer dominated BCDT. T2DT no longer dominated BCDT when the prevalence of Candida BSI was <2.4%, the number of reduced hospital days due to early treatment was <4.4 days, the cost of T2Candida test reagents was >$330, or the average daily costs of patients diagnosed in the ICU or the non-ICU ward was <$2,243 or $734, respectively.